NCT06267326 is a Phase 1, PHASE2 clinical trial of debridment in Mucormycosis; Rhinocerebral (Etiology), sponsored by Nasser Institute For Research and Treatment.

Who is sponsoring NCT06267326?

NCT06267326 is sponsored by Nasser Institute For Research and Treatment.

What drugs are being tested in NCT06267326?

Interventions in NCT06267326: debridment.

What condition does NCT06267326 study?

NCT06267326 studies Mucormycosis; Rhinocerebral (Etiology), COVID-19.

Is NCT06267326 still recruiting?

NCT06267326 is currently completed. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06267326

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

Completed Phase 1, PHASE2 Last updated 20 February 2024

What this trial tests

Phase 1, PHASE2 trial testing debridment in Mucormycosis; Rhinocerebral (Etiology) in 35 participants. Completed in 21 August 2023.

Timeline

23 May 2021

Primary endpoint
12 June 2022

21 August 2023

Quick facts

Lead sponsor	Nasser Institute For Research and Treatment
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	35
Start date	23 May 2021
Primary completion	12 June 2022
Estimated completion	21 August 2023
Sites	1 location across Egypt

Drugs / interventions tested

debridment

Conditions studied

Mucormycosis; Rhinocerebral (Etiology) — all drugs for Mucormycosis; Rhinocerebral (Etiology) →
COVID-19 — all drugs for COVID-19 →

Sponsor

Nasser Institute For Research and Treatment

Who can join

Adults 22 to 77, any sex, with Mucormycosis; Rhinocerebral (Etiology) or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Nasser Institute For Research and Treatment trials

Trials by the same sponsor.

NCT07078006 — Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06267326 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nasser Institute For Research and Treatment
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06267326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing